AZ-UNIVERSAL-ELECTRONICS
1.5.2020 22:17:07 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in universal control and sensing technologies for the smart home, has received five 2020 Red Dot Awards , one of the most prestigious international design awards, in the Product Design category. Products from UEI’s consumer brand, One For All , won four of the five awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200501005501/en/
The award-winning products were designed by UEI’s design team in the Netherlands, part of the global Designovation team which creates product designs based on user insights and innovative technology. Led by Rex Xu, Director of Design and User Experience, the team in the Netherlands works closely with UEI’s design offices in the U.S. and Hong Kong to ensure all products truly reflect global trends in design and technology.
“Winning five Red Dot Awards is a true honor and a testament to our design team’s exceptional talent,” said Xu. “Design is one of UEI’s key differentiators and we always create our designs with the user experience in mind. The team works under clear guiding principles of our successful Designovation formula which creates honest product designs based on true consumer insights applying the latest technology and design trends.”
Two of One For All’s TV stands were recognized with 2020 Red Dot Awards:
The Tripod Universal TV Stand fits televisions up to 65 inches, can swivel a true 360 degrees and blends into any corner with natural chestnut or oak wooden legs for a modern look.
The One For All Falcon Universal TV Stand supports televisions up to 70 inches and is designed to accommodate soundbars, streaming boxes and game consoles connected to the television. With its fabric skinned storage cover at the back of the television, cables are completely out of sight.
One For All also won two Red Dot awards for its market-leading digital TV antennas:
The Amplified Indoor TV Antenna features leading reception technology in a beautiful fabric skinned housing. With its homey design, it can hang on the wall, stand or lie flat while allowing for maximum channel coverage.
The darker colored Amplified Indoor TV Antenna offers a stylish look and unique signal level indicator that blends into the fabric housing. This ensures optimal signal and maximum number of available channels.
The fifth Red Dot Award is for UEI’s Kita premium Android TV voice remote control specifically designed for service providers with advanced video services that want a simplified user experience. In addition to supporting voice control and dedicated streaming app keys, this remote control features adaptive control which interacts with the television and only shows users the keys they need. It uses rechargeable technology in a slim housing, saving multiple batteries over the life of the product.
For more information about how to purchase these award-winning products, contact info@uei.com .
In 2019 One For All won Red Dot Awards for its Amplified Indoor Ball Design Antenna and One For All FLUX Gas Spring TV Wall Mount. With origins dating back to 1955, the Red Dot is established internationally as one of the most sought-after quality marks for outstanding design with annual competitions for Product Design, Brands and Communication, and Design Concept. Red Dot Award submissions are evaluated by a jury of independent designers, design professors and journalists.
All trademarks appearing herein are the property of their respective owners.
One For All is a registered trademark of Universal Electronics Inc.
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in universal control and sensing technologies for the smart home. The company designs, develops, manufactures and ships over 500 innovative products that are used by the world’s leading brands in the consumer electronics, subscription broadcast, security, home automation, hospitality and climate control markets. For more information, visit www.uei.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom